Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Crinetics Pharmaceuticals’s reported figures.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
FAQ
- What is Crinetics Pharmaceuticals's EBIT?
- Crinetics Pharmaceuticals (CRNX) reported EBIT of -$140.38M in Q1 2026.
- How has Crinetics Pharmaceuticals's EBIT changed year-over-year?
- Crinetics Pharmaceuticals's EBIT decreased by 26.0% year-over-year, from -$111.41M to -$140.38M.
- What is the long-term trend for Crinetics Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EBIT has grown at a 48.0% compound annual growth rate (CAGR), from -$107.7M to -$516.77M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Crinetics Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude